Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ALNYLAM PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for ALNYLAM PHARMACEUTICALS, INC.

ALNY

ALNYLAM PHARMACEUTICALS, INC.

About ALNYLAM PHARMACEUTICALS, INC.

Alnylam Pharmaceuticals, Inc. is a pioneering biopharmaceutical company specializing in RNA interference (RNAi) therapeutics. With five approved products, including ONPATTRO and AMVUTTRA, Alnylam targets rare diseases like hereditary transthyretin-mediated amyloidosis. The company aims to expand its pipeline with over 20 clinical programs, focusing on high unmet medical needs. Alnylam's strategic initiatives, including collaborations with Roche and Novartis, support its goal of becoming a top-tier biotech by 2025.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ALNYLAM PHARMACEUTICALS, INC.

1
1
ALNYLAM PHARMACEUTICALS, INC. Alnylam Pharmaceuticals Reports 96% Revenue Growth to $1.17 Billion in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
ALNYLAM PHARMACEUTICALS, INC. Alnylam Reports $3.71 Billion Revenue and Profitability for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
ALNYLAM PHARMACEUTICALS, INC. Alnylam Pharmaceuticals Reports 149% Revenue Growth to $1.25 Billion in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ALNYLAM PHARMACEUTICALS, INC. Alnylam Pharmaceuticals Reports 17% Revenue Growth to $773.7 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ALNYLAM PHARMACEUTICALS, INC. Alnylam Pharmaceuticals Reports $594.2M Revenue in Q1 2025, Driven by AMVUTTRA Sales

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ALNYLAM PHARMACEUTICALS, INC. Alnylam Pharmaceuticals Reports $278.1M Net Loss and 23% Revenue Growth in 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
ALNYLAM PHARMACEUTICALS, INC. Alnylam Pharmaceuticals Reports 34% Increase in Net Product Revenues, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments